- ORIC Pharmaceuticals press release (NASDAQ:ORIC): Q1 GAAP EPS of -$0.53.
- Cash, cash equivalents and investments totaled $208.9 million as of March 31, 2023, which the company expects will be sufficient to fund its operating plan into the first half of 2025.
- General and administrative (G&A) expenses were $6.2 million for the three months ended March 31, 2023, compared to $6.4 million for the three months ended March 31, 2022, a decrease of $0.3 million.
ORIC Pharmaceuticals GAAP EPS of -$0.53
Recommended For You
More Trending News
About ORIC Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| ORIC | - | - |
| ORIC Pharmaceuticals, Inc. | ||